The Indian Pharmaceutical Industry has witnessed robust growth over the past few decades and especially during the global covid-19 pandemic in recent time. It has shown tremendous progress in terms of infrastructure development, technology base creation, and a wide range of products including several novel covid-19 vaccines. India is among the top 10 formulation exporting countries in the world, fourth largest by volume, tenth largest by value, and is the largest ‘generic only’ exporter in the world, accounting for 20 percent of the global exports in generics. As a result India is recognized as “Pharmacy of the world” even by developed nations.
Significantly, one of the leading and emerging pharmaceutical merchant export startup organization who has successfully spread its footprints across 12 countries in Africa and South East Asia in short span is Atlanta Biological Pvt. Ltd.
Atlanta Biological was established in 2012 by its founding chairman, Arun Kumar Poddar; a well-known industrialist and philanthropist from Kolkata with its technical lead Hasanur Rahaman, a trained chemist and clinical scientist by profession, with the vision of narrowing the gap between the manufacturer and medical supply to patients by making proper use of the excess capacity of the pharmaceutical manufacturing plants, which results in significant cost cutting of generic medicine at least by 18-20 percent.
Unlike the other conventional pharmaceutical companies that focus on building new manufacturing facilities, Atlanta Biological lays its emphasis on positioning and strategic marketing of the branded generics, mainly Oncology, Anti-retro Viral products. Team Atlanta has selected 10 factories in India having there excess capacity of
productions and collaborated with them in Loan license or in long term Contract manufacturing engagement.
Hasanur adds "Initially, we had decided to build our manufacturing unit, but then we realized rather than to create another one, as India is equipped with around 20000 big and small category WHO GMP Certified pharmaceutical plants, why can't we use the excess manufacturing capacity of existing facilities, with our core expertise of strategic marketing and product positioning".
The core strength of the firm lies in the International marketing and right positioning of the Novel generics. With over 40 branded products sold worldwide, the firm supplies mainly to the private distributors, NGOs, several government organizations in East and West African countries. Our commitment to utmost quality and ethics leads to the pursuit of highly stringent standards in all our activities and future developments. All our products are manufactured considering WHO-GMP and other global quality standards such as PIC/s, US-FDA and EU-GMP.
-
The core strength of the firm lies in out of the box vision and strategic positioning of the product that meets the highest quality standards
Strategic Approach Towards Cost-Efficiency
Africa is the core business focus of the organisation as it is experiencing a high increment in healthcare expenses, mainly because of absence of local manufacturing facilities. Rahaman has added that, as per his observation “We are lucky to be in India as in African continent, a basic drug like Paracetamol even can cost up to 10 times more compared to what we are paying in India”. To address this major health care issue, Atlanta Biological brings in a very cost-effective approach, providing the high quality pharmaceutical products at a much-substituted price, with a mission to improve the supplies of medicine to the people in Africa who are in critical need of basic medicines.
Atlanta Biological is presently working rigorously in the realm of bio-similar projects especially in Vaccine development and Oncology care segment, with an aim to make the treatment affordable by the common people. It is presently under advanced discussion with a leading US based universities for their technology transfer of an ovel vaccines and few bio-similar products. Also to accomplish such enormous project in African region which evidently needs a significant level of financial backing besides scientific acquaintance, to achieve this Atlanta Biological is approaching for a strategic collaborations with various Multilateral DFIs and African Development Corporations to make this much needed project into a reality at the earliest.
